Earnings Outlook For Revolve Group

Revolve Group (NYSE:RVLV) is set to give its latest quarterly earnings report on Thursday, 2023-02-23. Here’s what investors…

Revolve Group (NYSE:RVLV) is set to give its latest quarterly earnings report on Thursday, 2023-02-23. Here’s what investors need to know before the announcement.

Analysts estimate that Revolve Group will report an earnings per share (EPS) of $0.10.

Revolve Group bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company beat EPS by $0.07, which was followed by a 3.62% increase in the share price the next day.

Here’s a look at Revolve Group’s past performance and the resulting price change:

Quarter Q3 2022 Q2 2022 Q1 2022 Q4 2021
EPS Estimate 0.09 0.31 0.27 0.18
EPS Actual 0.16 0.22 0.30 0.39
Price Change % 3.62% -13.6% -15.05% 3.01%

eps graph

Stock Performance

Shares of Revolve Group were trading at $24.86 as of February 21. Over the last 52-week period, shares are down 51.34%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

To track all earnings releases for Revolve Group visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended November 2023, And Year-To-Date Through November 30, 2023

Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute

SCLX